Chemical Biology Program
The Minkui Luo Lab
The Luo Lab is interested in developing and leveraging novel approaches at the interface of chemistry and biology to annotate functional roles of epigenetic modulators. Epigenetic regulation is essential for maintaining cellular fates and its dysregulation has been associated with various diseases including cancer. Among key epigenetic modulators are diverse protein methyltransferases/demethylases and methyl-arginine/lysine (Rme/Kme) effector proteins. With novel chemical tools developed in-house, we aim to systematically interrogate Rme/Kme-involved epigenetics with emphasis on novel molecular mechanisms and biological outcomes. The Luo laboratory is also interested in designing and synthesizing epigenetic inhibitors with the emphasis of the distinct modes of action in disease-relevant contexts. Researchers in the Luo Lab with expertise in chemistry, biochemistry and biology work in a highly collaborative manner to develop unprecedent chemical reagents for biological discovery, elucidate disease-causing mechanisms with molecular details, and explore novel treatments against cancer.
Cai XC, Zhang T, Kim EJ, Jiang M, Wang K, Wang J, Chen S, Zhang N, Wu H, Li F, Dela Seña CC, Zeng H, Vivcharuk V, Niu X, Zheng W, Lee JP, Chen Y, Barsyte D, Szewczyk M, Hajian T, Ibáñez G, Dong A, Dombrovski L, Zhang Z, Deng H, Min J, Arrowsmith CH, Mazutis L, Shi L, Vedadi M, Brown PJ, Xiang J, Qin LX, Xu W, Luo M. A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion. Elife. 2019 Oct 28;8:e47110. This work was highlighted by Elife Digest.
Chen S, Kapilashrami K, Senevirathne C, Wang Z, Wang J, Linscott JA, Luo M. Substrate-Differentiated Transition States of SET7/9-Catalyzed Lysine Methylation. J Am Chem Soc. 2019 May 22;141(20):8064-8067.
Chen S, Wiewiora RP, Meng F, Babault N, Ma A, Yu W, Qian K, Hu H, Zou H, Wang J, Fan S, Blum G, Pittella-Silva F, Beauchamp KA, Tempel W, Jiang H, Chen K, Skene RJ, Zheng YG, Brown PJ, Jin J, Luo C, Chodera JD, Luo M. The dynamic conformational landscape of the protein methyltransferase SETD8. Elife. 2019 May 13;8:e45403. This work was highlighted by Elife Digest, News of Shanghai Institute of Materia Medica, MSKCC Blog, and TPCB Webpage.
Minkui Luo, PhD
- Chemical Biologist Minkui Luo develops cutting-edge tools, technologies and concepts to annotate functions of protein-posttranslational modifications and designs inhibitors for cancer therapies.
- BS, Fudan University
- PhD, Princeton University
- Maximizing Investigators’ Research Award (R35), NIGMS/NIH (2019)
- Eli Lilly Award in Biological Chemistry, American Chemical Society (2015)
- Clinical & Translational Science Center Novel Award, Weill Cornell Medical College (2014)
- Basil O'Connor Starter Scholar, March of Dimes Birth Defects Foundation (2011)
- Director’s New Innovator Award, National Institutes of Health (2010)
- Alfred W. Bressler Scholar, Alfred W. Bressler Scholars Endowment Fund (2010)
- The V Scholar Award, V Foundation for Cancer Research (2009)
- Outstanding Postdoctoral Research Prize, Albert Einstein College of Medicine (2007)
- Best Presentation Award, 3rd ACS Annual Metropolitan New York Area Poster Program for Graduate Students in the Chemical Sciences (2003)
- Rohm & Haas Fellowship, Fudan University (1998)
- Du Pont Fellowship, Fudan University (1998)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Minkui Luo discloses the following relationships and financial interests:
Provision of Services
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.